Literature DB >> 9286653

Surgical management of retroperitoneal tumors with vena caval thrombus in the inferior cava using cardiopulmonary bypass, arrested circulation and profound hypothermia.

F I Rodríguez-Rubio1, J I Abad, G Sanz, F Diez-Caballero, A Martín-Marquina, D Rosell, J E Robles, J J Zudaire, R Llorens, J M Berián.   

Abstract

OBJECTIVE: It was our aim to review our surgical experience with retroperitoneal tumors extending to the vena cava by using cardiopulmonary bypass, deep hypothermia and circulatory arrest.
METHOD: We performed this procedure in 15 patients. The ages ranged between 16 and 70 years. The primary malignancies were renal cell carcinoma (n = 13), Wilms' tumor (n = 1) and paratesticular rhabdomyosarcoma (n = 1).
RESULTS: There were no operative deaths. One patient died on the fourth postoperative day because of pulmonary embolization. The most common postoperative complications were: 1 patient required surgical reexploration because of hemorrhage, there was transitory renal failure in 3 patients, 1 patient developed a postoperative reactive psychosis and 1 patient developed a subclinical pericarditis.
CONCLUSION: We believe that the resection of retroperitoneal malignancies with venous tumor thrombus extension offers, in selected patients, the only chance of reasonable long-term survival. The application of a cardiopulmonary bypass and hypothermia in high level vena cava thrombi is an important advance that has improved the safety and technical efficacy of a difficult surgical undertaking.

Entities:  

Mesh:

Year:  1997        PMID: 9286653

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  1 in total

1.  Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors.

Authors:  Saniye Ekinci; Ibrahim Karnak; F Cahit Tanyel; M Emin Senocak; Tezer Kutluk; Münevver Büyükpamukçu; Nebil Büyükpamukçu
Journal:  Pediatr Surg Int       Date:  2006-01-03       Impact factor: 1.827

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.